| Similar Articles |
|---|
 |
The Motley Fool
October 24, 2005
Brian Gorman |
PAREXEL Gets Squeezed First-quarter results reflect tough competition in the contract research industry. For now, this may be one stock to avoid.   |
The Motley Fool
January 25, 2006
Brian Gorman |
PAREXEL Recovers The clinical research services company is in better shape, but it still has progress to make. Investors should approach the company with some caution. |
The Motley Fool
April 27, 2006
Brian Gorman |
PAREXEL Can Do Better Despite heartening recent results, the drug research company's profitability could be better. These shares aren't terribly cheap and it appears that investors' expectations are running high. |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
The Motley Fool
November 1, 2005
Brian Gorman |
Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD. |
The Motley Fool
June 10, 2005
Brian Gorman |
PAREXEL's New Risk The contract pharmaceutical research services provider is realigning its business, but even with reduced U.S. operations, it faces increased risk. Investors, beware. |
The Motley Fool
February 14, 2006
Brian Gorman |
Kendle's on Solid Ground The contract research services outfit is on track for another good year. Investors, take note. |
The Motley Fool
March 20, 2006
Brian Gorman |
Much Ado About PAREXEL The contract research services provider's shares have been on a roller coaster ride lately, but the ups and downs don't make a lot of sense. Investors, take note. |
The Motley Fool
October 29, 2009
Robert Steyer |
Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle. |
The Motley Fool
January 13, 2011
Brian Orelli |
This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars. |
The Motley Fool
April 24, 2009
Robert Steyer |
Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services. |
The Motley Fool
February 15, 2005
Brian Gorman |
Kendle Grows With Client Base The contract drug research company shares surged as the firm showed signs of new life. |
The Motley Fool
July 22, 2009
Robert Steyer |
Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry. |
The Motley Fool
July 6, 2004
Brian Gorman |
Hidden Drug Costs Regulatory requirements play an important role in drug expenses. |
The Motley Fool
October 23, 2009
Robert Steyer |
Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends. |
The Motley Fool
July 29, 2005
Stephen Ellis |
eResearch Misses a Beat Is eResearch Technology a dirt-cheap company or value trap? There are good reasons to suggest that the provider of ECG collection and interpretation services to the pharmaceutical industry does not deserve the shellacking that it has been receiving over the past year. |
The Motley Fool
July 27, 2011
Michael Olsen |
Rising Stars Buy: Icon Icon, the fourth-largest CRO, sits among the global elite and makes for a healthy investment. |
The Motley Fool
August 1, 2008
Brian Orelli |
Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit. |
The Motley Fool
January 27, 2011
Seth Jayson |
Here's How Pharmaceutical Product Development May Be Failing You Here's the current margin snapshot for Pharmaceutical Product Development and some of its sector and industry peers and direct competitors. |
Pharmaceutical Executive
October 1, 2011 |
The Enterprising CRO Josef von Rickenbach, President & CEO of Parexel continues to lead the company, which has morphed from functional service provider to full-service global organization. |
The Motley Fool
October 3, 2011
Brian D. Pacampara |
Pharmaceutical Product Development Shares Soared: What You Need to Know Shares of Pharmaceutical Product Development skyrocketed 25% Monday after The Carlyle Group and Hellman & Friedman LP agreed to buy the health-care research specialist for $3.8 billion. |
